[go: up one dir, main page]

AR079945A1 - PIRAZINE DERIVATIVES AS INHIBITORS OF GLUCOGENO SINTASA QUINASA 3 (GSK3) - Google Patents

PIRAZINE DERIVATIVES AS INHIBITORS OF GLUCOGENO SINTASA QUINASA 3 (GSK3)

Info

Publication number
AR079945A1
AR079945A1 ARP110100182A ARP110100182A AR079945A1 AR 079945 A1 AR079945 A1 AR 079945A1 AR P110100182 A ARP110100182 A AR P110100182A AR P110100182 A ARP110100182 A AR P110100182A AR 079945 A1 AR079945 A1 AR 079945A1
Authority
AR
Argentina
Prior art keywords
glucogeno
sintasa
quinasa
gsk3
inhibitors
Prior art date
Application number
ARP110100182A
Other languages
Spanish (es)
Inventor
Tao Feng
Hitesh Jayantilal Sanganee
Hiroki Wada
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR079945A1 publication Critical patent/AR079945A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Derivados de pirazina de formula (1) o sales farmacéuticamente aceptables de los mismos en donde n es 2 o 3; m es 2 o 3, Re s -CH3 o -CH2-CH3, y su uso en la fabricacion de un medicamento para su uso en el tratamiento de trastornos o afecciones oseos.Pyrazine derivatives of formula (1) or pharmaceutically acceptable salts thereof where n is 2 or 3; m is 2 or 3, Re s -CH3 or -CH2-CH3, and its use in the manufacture of a medicament for use in the treatment of bone disorders or conditions.

ARP110100182A 2010-01-19 2011-01-19 PIRAZINE DERIVATIVES AS INHIBITORS OF GLUCOGENO SINTASA QUINASA 3 (GSK3) AR079945A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29619610P 2010-01-19 2010-01-19

Publications (1)

Publication Number Publication Date
AR079945A1 true AR079945A1 (en) 2012-02-29

Family

ID=43743548

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110100182A AR079945A1 (en) 2010-01-19 2011-01-19 PIRAZINE DERIVATIVES AS INHIBITORS OF GLUCOGENO SINTASA QUINASA 3 (GSK3)

Country Status (14)

Country Link
US (2) US8198285B2 (en)
EP (1) EP2526097A1 (en)
JP (1) JP2013517321A (en)
KR (1) KR20120120307A (en)
CN (1) CN102812017A (en)
AR (1) AR079945A1 (en)
AU (1) AU2011208530A1 (en)
BR (1) BR112012017884A2 (en)
CA (1) CA2786520A1 (en)
MX (1) MX2012008328A (en)
RU (1) RU2012135093A (en)
TW (1) TW201130814A (en)
UY (1) UY33191A (en)
WO (1) WO2011089416A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6054954B2 (en) * 2011-05-23 2016-12-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Pyridine- and pyrazine derivatives
DK2970890T3 (en) 2013-03-14 2020-05-04 Brigham & Womens Hospital Inc COMPOSITIONS AND PROCEDURES FOR THE PROMOTION AND CULTIVATION OF EPITHEL STEM CELLS
AU2015311816B2 (en) 2014-09-03 2019-04-04 Massachusetts Institute Of Technology Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
AU2017205194A1 (en) 2016-01-08 2018-07-19 Massachusetts Institute Of Technology Production of differentiated enteroendocrine cells and insulin producing cells
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
MX390321B (en) 2016-12-30 2025-03-20 Frequency Therapeutics Inc 1H-PYRROL-2,5-DIONE COMPOUNDS AND METHODS OF USING SAME TO INDUCE SELF-RENEWAL OF SUPPORT STEM/PROGENITOR CELLS.
CA3109647A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
EP3837351A1 (en) 2018-08-17 2021-06-23 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
AU719434B2 (en) 1996-02-13 2000-05-11 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
ES2169355T3 (en) 1996-03-05 2002-07-01 Astrazeneca Ab DERIVATIVES OF 4-ANILINOQUINAZOLINA.
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
MXPA01008182A (en) 1999-02-10 2003-08-20 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors.
HK1046276A1 (en) 2000-02-05 2003-01-03 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
UA73993C2 (en) 2000-06-06 2005-10-17 Астразенека Аб Quinazoline derivatives for the treatment of tumours and a pharmaceutical composition
MXPA02012903A (en) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors.
CA2411160A1 (en) 2000-07-07 2002-01-17 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
SE0102438D0 (en) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102439D0 (en) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
CN100409840C (en) 2002-01-10 2008-08-13 霍夫曼-拉罗奇有限公司 Application of GSK-3β inhibitor in preparation of medicine for increasing bone formation
JP4414232B2 (en) 2002-03-05 2010-02-10 イーライ リリー アンド カンパニー Kinase inhibitor
AU2003234464B2 (en) 2002-05-03 2009-06-04 Exelixis, Inc. Protein kinase modulators and methods of use
SE0203753D0 (en) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203754D0 (en) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203752D0 (en) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
BRPI0408251A (en) 2003-03-11 2006-03-01 Pfizer Prod Inc pyrazine compounds as transforming growth factor (tgf) inhibitors
AU2004274861A1 (en) 2003-06-06 2005-03-31 Wyeth Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby
EP1653970A4 (en) 2003-08-13 2008-10-15 Novartis Vaccines & Diagnostic GSK-3 INHIBITORS AND USES
AU2004268621C1 (en) 2003-08-29 2011-08-18 Exelixis, Inc. c-Kit modulators and methods of use
US20050064044A1 (en) 2003-09-19 2005-03-24 Georges Rawadi GSK-3beta inhibitors in the treatment of bone-related diseases
JP2007524682A (en) 2004-02-12 2007-08-30 メルク　エンド　カムパニー　インコーポレーテッド Bipyridylamide as a regulator of metabotropic glutamate receptor-5
TW200800203A (en) * 2006-03-08 2008-01-01 Astrazeneca Ab New use
AU2008221263B2 (en) * 2007-03-01 2012-02-23 Novartis Ag Pim kinase inhibitors and methods of their use
WO2010054398A1 (en) 2008-11-10 2010-05-14 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase

Also Published As

Publication number Publication date
CA2786520A1 (en) 2011-07-28
UY33191A (en) 2011-08-31
BR112012017884A2 (en) 2019-09-24
AU2011208530A1 (en) 2012-08-09
WO2011089416A1 (en) 2011-07-28
MX2012008328A (en) 2012-08-08
US8198285B2 (en) 2012-06-12
RU2012135093A (en) 2014-03-10
US20130123275A1 (en) 2013-05-16
EP2526097A1 (en) 2012-11-28
US20120022082A1 (en) 2012-01-26
CN102812017A (en) 2012-12-05
TW201130814A (en) 2011-09-16
JP2013517321A (en) 2013-05-16
KR20120120307A (en) 2012-11-01

Similar Documents

Publication Publication Date Title
AR079945A1 (en) PIRAZINE DERIVATIVES AS INHIBITORS OF GLUCOGENO SINTASA QUINASA 3 (GSK3)
CY1123637T1 (en) ARGININE METHYL TRANSFER INHIBITORS AND THEIR USES
CR20150472A (en) USE OF PIRAZOLOPIRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kd-RELATED DISORDERS
UY30846A1 (en) OXINDOL DERIVATIVES REPLACED, MEDICINES THAT UNDERSTAND AND USE THEMSELVES
NI201200184A (en) MORPHOLINOPYRIMIDINES AND THEIR USE IN THERAPY
CR20150628A (en) DERIVATIVES OF PIRAZOLOPIRROLIDINE AND ITS USE IN THE TREATMENT OF DISEASES
UY33353A (en) SUITABLE COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS AND PREPARATION METHODS
ECSP13012611A (en) PIRAZOL-AMINOPIRIMIDINE DERIVATIVES AS MODULATORS OF THE LRRK2
ECSP16005566A (en) SULFONAMIDES AS SODIUM CHANNEL MODULATORS
MX388946B (en) 19-ALKOXY-17 SUBSTITUTED NEUROACTIVE STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING THE SAME.
GT201300243A (en) RAMIFIED 3-PHENYLPROPIONIC ACID DERIVATIVES AND ITS USE
CR11518A (en) CARBAMOIL COMPOUNDS AS DGAT1 190 INHIBITORS
CL2019002900A1 (en) Benzoazepine analogs as bruton tyrosine kinase inhibitors.
CO6480932A2 (en) ANTAGONISTS OF THE HEDGEHOG TRAJECTORY OF DISTTITUTED FTALAZINA.
CR11684A (en) REPLACED DIHYDROPIRAZOLONES OF HIF-PROPIL-4- AS HYDROXYLASE INHIBITORS
UY32190A (en) DERIVATIVES OF ANILINA-PYRIMIDINE SUBSTITUTED WITH SULFOXIMINE AS INHIBITORS OF CYCLINE DEPENDENT KINASES (CDK), PRODUCTION AND USE OF THE SAME AS MEDICINAL PRODUCTS
UY31228A1 (en) ARILOXAZOLES REPLACED AND ITS USE
DOP2014000036A (en) PIRIDAZINONE COMPOUNDS AND ITS USE AS DAAO INHIBITORS
GT201400085A (en) ADRENOMEDULINE PROMOTE BASED ON POLYETHYLENE GLYCOL AND ITS USE
ECSP088700A (en) 4-PHENYL-TIAZOL-5-CARBOXILIC ACIDS AND 4-PHENYL-TIAZOL-5-CARBOXILIC ACIDS AS INHIBITORS OF THE PLK1
UY31922A (en) COMPOUNDS
CL2015002346A1 (en) Estra-1,3,5 (10), 16-tetraeno-3-carboxamides for the inhibition of 17b-hydroxysteroid dehydrogenase (akr1 c3)
PA8821301A1 (en) INHIBITORS BASED ON HYDROXAMATE DEACETILASES B
CY1120133T1 (en) Pyridazines as DAAO Enzyme Inhibitors
UY32954A (en) PYRIMIDINES REPLACED WITH ADAMANTILIMINOCARBONILO AS INHIBITORS OF 11-ß-HSD1 826 ?.

Legal Events

Date Code Title Description
FB Suspension of granting procedure